Connect with us
nairametrics

Coronavirus

Covid-19: Russia says its Sputnik V vaccine is 92% effective

Russia’s COVID-19 vaccine, Sputnik V, has been declared by its developers to be 92% effective.

Published

on

COVID-19 vaccine from Russia

The developer of Russia’s flagship vaccine against Covid-19, Sputnik V, has disclosed that it is 92% effective in protecting people from the virus infections.

As the country pushes for a top slot in the fight against the coronavirus after a rival product by Pfizer Inc. reported a similar breakthrough.

This announcement was made by its developers, Gamaleya Research Institute of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), through a tweet post on Wednesday, November 11, 2020.

The 2 organizations who are backing its development and marketing it globally said the preliminary Phase 3 findings are based on results from 20,000 volunteers who were given the first dose, including more than 16,000 who also received a second injection.

According to a report from Bloomberg, the statement says that the data is based on results 21 days after the initial injection and will be published in a peer-reviewed medical journal.

GTBank 728 x 90

The 92% efficacy rate was based on 20 confirmed Covid-19 cases split across vaccinated subjects who got two doses and those who got the placebo.

This is significantly lower than the 94 infections in the trial of the Covid-19 vaccine developed by Pfizer Inc and BioNTech. Pfizer said it would continue with its trial until there were 164 Covid-19, in order to confirm its efficacy rate

The developers who revealed that no unexpected adverse events have been reported with monitoring continuing, also said the trial is to include a total of 40,000 subjects although not all have yet been vaccinated.

Coronation ads

The shots have also been given to health workers, teachers and officials outside the trial, with preliminary observations showing effectiveness over 90%, the Health Ministry said hours after Pfizer’s announcement this week.

RDIF said the Russian trial would continue for 6 more months and data from the trials will also be published in a leading international medical journal following a peer review.

This announcement from Russia is coming 2 days after Nairametrics had reported that Pfizer’s Covid-19 vaccine candidate, which is developed in collaboration with BioNTech SE, is at least 90% effective.

According to an interim analysis published this week in what was described as the most encouraging scientific evidence supporting any vaccination to date.

It can be recalled that Russia was the first in the world to register its Covid-19 vaccine, Sputnik V, for public use in August, although the approval came before the start of the large scale trial in September.

Jaiz bank ads

Scientists and pharmaceutical companies have raised serious concerns about the speed at which Russia gave regulatory approval for the drug and launching mass vaccination programme before full trials to test its safety and efficacy had been completed.

Stanbic IBTC

With the world’s fifth-largest number of Covid-19 cases, Russia is also hoping to capture a share of the global market for a tool to control the pandemic that has killed more than 1.2 million people globally

After it was approved for use, Sputnik V has faced challenges ramping up production as other inoculations globally prepare for widespread roll-out.

Chike Olisah is a graduate of accountancy with over 15 years working experience in the financial service sector. He has worked in research and marketing departments of three top commercial banks. Chike is a senior member of the Nairametrics Editorial Team. You may contact him via his email- [email protected]

Click to comment

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Coronavirus

Covid-19: Victims Support Fund launches N3.3 billion intervention fund

The VSF has launched a N3.3 billion intervention fund, targeting one million households most affected by the COVID-19 pandemic in Nigeria.

Published

on

Covid-19: Victims Support Fund

The Victims Support Fund (VSF), a foundation for supporting victims of terrorism has announced that the launch of a N3.3 billion COVID-19 intervention fund, targeting one million households most affected by the pandemic in Nigeria.

This was disclosed by Mrs. Toyosi Akerele-Ogunsuji, Chairperson, VSF Task Force on COVID-19, on Saturday in Kano.

Mrs. Akerele-Ogunsuji disclosed on Saturday that VSF has already spent N1.8 billion in the first phase of its COVID-19 intervention through the provision of food and other relief materials, adding that N832 million was spent under the second phase of the programme.

READ: Agriculture: AfDB to invest $25 billion in Nigeria, Senegal, 3 others

She added that for the 3rd phase of the scheme, N1.3 billion will be spent until the end of the year.

GTBank 728 x 90

“The total amount will be around N3.3 billion. It includes the money spent on the provision of 54 solar powered boreholes installed in schools across 18 states in the six geo-political zones of the county.

“The VSF is also donating 60, 000 pieces of COVID-19 rapid test kits to support opening of the orientation camps of the National Youth Service Corps (NYSC) in the coming weeks.

READ: Nigeria spends N8 billion annually to import vaccines 

Coronation ads

“We are targeting indigent and vulnerables households in the country, that is very important to us, and by the time we have done this intervention we will have over one million individuals who have been touched by the VSF interventions,” she said.

She also revealed that the fund has also provided medical items and Personal Protective Equipment (PPE) to healthcare workers, in 16 of the 30 states in the six geo-political zones of the country.

READ: $66.5 billion worth of Bitcoin lost forever

What you should know 

Victims Support Fund, joins other private and public sector initiatives including the  Coalition Alliance Against COVID-19 CACOVID which the Central Bank of Nigeria (CBN) revealed has so far incurred an expenditure of N43.27billion on the acquisition of, not only medical equipment and supplies but also food palliatives for vulnerable Nigerians.

Jaiz bank ads

READ: Terrorism: Nigeria records 39.1% reduction in deaths – GTI Report

Stanbic IBTC

Nairametrics reported that CACOVID  announced plans to deploy over N150 billion towards the setting up and implementation of a youth development programme. It also announced they have budgeted nothing less than N250 billion to rehabilitate damaged police stations across the country and solve the issue of unemployment.

Continue Reading

Coronavirus

COVID-19 Update in Nigeria

On the 28th of November 2020, 110 new confirmed cases were recorded in Nigeria

Published

on

The spread of novel Corona Virus Disease (COVID-19) in Nigeria continues to record significant increases as the latest statistics provided by the Nigeria Centre for Disease Control reveal Nigeria now has 67,330 confirmed cases.

On the 28th of November 2020, 110 new confirmed cases were recorded in Nigeria, having carried out a total daily test of 7,101 samples across the country.

To date, 67,330 cases have been confirmed, 62,819 cases have been discharged and 1,171 deaths have been recorded in 36 states and the Federal Capital Territory. A total of 756,237 tests have been carried out as of November 28th, 2020 compared to 749,136 tests a day earlier.

COVID-19 Case Updates- 28th November 2020,

  • Total Number of Cases – 67,220
  • Total Number Discharged – 62,686
  • Total Deaths – 1,171
  • Total Tests Carried out – 756,237

According to the NCDC, the 110 new cases were reported from 11 states- Lagos (26), FCT (23), Kaduna (20), Katsina (11), Ogun (7), Ekiti (6), Plateau (5), Rivers (4) Kano (3), Nasarawa (3) and Niger (2).

Meanwhile, the latest numbers bring Lagos state total confirmed cases to 23,190, followed by Abuja (6,767), Plateau (3,857), Oyo (3,721), Kaduna (3,064), Rivers (2,977), Edo (2,696), Ogun (2,222), Delta (1,824), Kano (1,794), Ondo (1,728), Enugu (1,332),  Kwara (1,096), Ebonyi (1,055), Katsina (1,025), Osun (945), Gombe (938). Abia (926), Bauchi (770), and Borno (745).

GTBank 728 x 90

Imo State has recorded 662 cases, Benue (496), Nasarawa (491), Bayelsa (445),  Ekiti (365), Akwa Ibom (339), Jigawa (331), Niger (298), Anambra (285), Adamawa (261), Sokoto (165), Taraba (159), Yobe (94), Kebbi (93), Cross River (90), Zamfara (79), while Kogi state has recorded 5 cases only.

READ ALSO: COVID-19: Western diplomats warn of disease explosion, poor handling by government

Lock Down and Curfew

In a move to combat the spread of the pandemic disease, President Muhammadu Buhari directed the cessation of all movements in Lagos and the FCT for an initial period of 14 days, which took effect from 11 pm on Monday, 30th March 2020.

Coronation ads

The movement restriction, which was extended by another two weeks period, has been partially put on hold with some businesses commencing operations from May 4. On April 27th, 2020, Nigeria’s President, Muhammadu Buhari declared an overnight curfew from 8 pm to 6 am across the country, as part of new measures to contain the spread of the COVID-19. This comes along with the phased and gradual easing of lockdown measures in FCT, Lagos, and Ogun States, which took effect from Saturday, 2nd May 2020, at 9 am.

On Monday, 29th June 2020 the federal government extended the second phase of the eased lockdown by 4 weeks and approved interstate movement outside curfew hours with effect from July 1, 2020. Also, on Monday 27th July 2020, the federal government extended the second phase of eased lockdown by an additional one week.

On Thursday, 6th August 2020 the federal government through the secretary to the Government of the Federation (SGF) and Chairman of the Presidential Task Force (PTF) on COVID-19 announced the extension of the second phase of eased lockdown by another four (4) weeks.

READ ALSO: Bill Gates says Trump’s WHO funding suspension is dangerous

Jaiz bank ads

 

Stanbic IBTC

 

 

 

Continue Reading

Coronavirus

Covid-19: UK to approve Pfizer, BioTNech vaccine, to start immunization December 7

The UK government is set to approve the COVID-19 vaccine developed by BioNTech SE and Pfizer Inc next week.

Published

on

Covid-19: AstraZeneca vaccine gets huge boost, produces immune response in elderly, Vaccine, COVID-19: Russia to roll out vaccine in September ahead of the West 

The global reception of the Covid-19 vaccine developed by Pfizer Inc in collaboration with BioNTech following the positive outcome of its phase 3 trial, seems to have intensified as it is set for approval by the UK medical regulator.

According to Reuters, a report from Financial Times on Saturday suggests that deliveries would commence within hours of the authorization with the first immunizations using the BioNTech and Pfizer vaccine possibly taking place from December 7.

The UK Prime Minister, Boris Johnson, had earlier in the day, named Nadhim Zahawi, who is the current junior business minister, as the minister responsible for the deployment of COVID-19 vaccines.

The UK government has placed an order for 40 million doses of the Pfizer and BioNTech vaccine, which has been found to be 95% effective in the final analysis of the phase 3 trials in preventing the spread of a virus that has killed over 1.4 million people across the world with its devastating impact on the global economy.

The UK government had on November 20, formally asked its medical regulator, the Medicines and Healthcare Products Regulatory Agency (MHRA), to conduct a study of the Pfizer-BioNTech COVID-19 vaccine with a view to determining its suitability, the first step in making it available outside the United State

GTBank 728 x 90

The government which had secured 100 million doses of the Covid-19 vaccine developed by AstraZeneca and University of Oxford had also asked the regulator on Friday to assess the vaccine for a possible rollout before Christmas.

What you should know: The US drugmaker, Pfizer Inc, on November 18, 2020, announced that a final analysis of clinical-trial data of its experimental Covid-19 vaccine, which it is developing in collaboration with BioTNech, showed it was 95% effective, thereby paving the way for the company to apply for the first U.S. regulatory authorization for a coronavirus shot.

Pfizer said they had no serious safety concerns in a trial that involves almost 44,000 participants as their vaccine protected people of all ages and ethnicities.

Coronation ads

Continue Reading